Status:
UNKNOWN
Relmacabtagene Autoleucel in Patients With LBCL
Lead Sponsor:
Shanghai Ming Ju Biotechnology Co., Ltd.
Conditions:
Large B-cell Lymphoma
Eligibility:
All Genders
18+ years
Brief Summary
To evaluate the efficacy and safety of Relmacabtagene autoleucel for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma (LBCL) in real-world
Detailed Description
This is a post-marketing, multicenter, observational real-world study, including prospective and retrospective studies. The purpose of this study is to collect efficacy and safety data over a 6-month ...
Eligibility Criteria
Inclusion
- Adult patients with established r/r LBCL;
- Patients already treated with commercially available Relmacabtagene Autoleucel
Exclusion
- No
Key Trial Info
Start Date :
December 28 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06142175
Start Date
December 28 2022
End Date
December 31 2024
Last Update
March 28 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,
Shanghai, Shanghai Municipality, China, 200025